Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing

Oral Oncology

Volumn 45, Issue 1, 2009, Pages 16-22

  Huang, Shiang Fu ^a,b   Chen, I How ^a   Liao, Chun Ta ^a   Wang, Hung Ming ^a   Liou, Saou Hsing ^c   Hsieh, Ling Ling ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Disease onset; Disease free survival; MDM2 SNP 309; Oral squamous cell carcinoma; p53 mutation

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; BETEL NUT; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRINKING BEHAVIOR; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ONSET AGE; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; TAIWAN; TUMOR DIFFERENTIATION;

ARECA; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 57549109111     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.03.006     Document Type: Article

References (45)

1. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
2. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
3. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., and Vogelstein B. A model for p53-induced apoptosis. Nature 389 (1997) 300-305
4. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
5. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14 (2000) 981-993
6. Mirza A., Wu Q., Wang L., McClanahan T., Bishop W.R., Gheyas F., et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22 (2003) 3645-3654
7. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
8. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
9. Royds J.A., and Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 13 (2006) 1017-1026
10. Menin C., Scaini M.C., De Salvo G.L., Biscuola M., Quaggio M., Esposito G., et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98 (2006) 285-288
11. Boersma B.J., Howe T.M., Goodman J.E., Yfantis H.G., Lee D.H., Chanock S.J., et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98 (2006) 911-919
12. Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66 (2006) 5104-5110
13. Ko Y.C., Huang Y.L., Lee C.H., Chen M.J., Lin L.M., and Tsai C.C. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24 (1995) 450-453
14. Duke J.A. Handbook of phytochemical constituents of GRAS herbs and other economic plants (1992), CRC Press, Boca Raton, FL
15. Nunez-de la Mora A., Chatterton R.T., Mateo E.T., Jesmin F., and Bentley G.R. Effect of chewing betel nut on measurements of salivary progesterone and estradiol. Am J Phys Anthropol 132 (2007) 311-315
16. Hsieh L.L., Chien H.T., Chen I.H., Liao C.T., Wang H.M., Jung S.M., et al. The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomark Prev 12 (2003) 439-443
17. Hsieh L.L., Liou S.H., Chen Y.H., Tsai L.C., Yang T., and Wu T.N. Association between aminolevulinate dehydrogenase genotype and blood lead levels in Taiwan. J Occup Environ Med 42 (2000) 151-155
18. Liao H.K., Su Y.N., Kao H.Y., Hung C.C., Wang H.T., and Chen Y.J. Parallel minisequencing followed by multiplex matrix-assisted laser desorption/ionization mass spectrometry assay for beta-thalassemia mutations. J Human Genet 50 (2005) 139-150
19. Stanssens P., Zabeau M., Meersseman G., Remes G., Gansemans Y., Storm N., et al. High-throughput MALDI-TOF discovery of genomic sequence polymorphisms. Genome Res 14 (2004) 126-133
20. Hsieh L.L., Wang P.F., Chen I.H., Liao C.T., Wang H.M., Chen M.C., et al. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 22 (2001) 1497-1503
21. Hsieh L.L., Huang T.H., Chen I.H., Liao C.T., Wang H.M., Lai C.H., et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Brit J Cancer 92 (2005) 30-35
22. Stoll C., Baretton G., and Lohrs U. The influence of p53 and associated factors on the outcome of patients with oral squamous cell carcinoma. Virchows Arch 433 (1998) 427-433
23. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., and Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95 (1998) 15608-15612
24. Ganguli G., Abecassis J., and Wasylyk B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J 19 (2000) 5135-5147
25. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65 (2005) 9582-9587
26. Dazard J.E., Piette J., Basset-Seguin N., Blanchard J.M., and Gandarillas A. Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size. Oncogene 19 (2000) 3693-3705
27. Myers J.N., Greenberg J.S., Mo V., and Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 92 (2001) 3030-3036
28. Carter R.L., Barr L.C., O'Brien C.J., Soo K.C., and Shaw H.J. Transcapsular spread of metastatic squamous cell carcinoma from cervical lymph nodes. Am J Surg 150 (1985) 495-499
29. Agarwal S., Mathur M., Srivastava A., and Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. Oral Oncol 35 (1999) 209-216
30. Zhou G., Zhai Y., Cui Y., Zhang X., Dong X., Yang H., et al. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 13 (2007) 2627-2633
31. Zhang L., and Hill R.P. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 64 (2004) 4180-4189
32. Zietz C., Rossle M., Haas C., Sendelhofert A., Hirschmann A., Sturzl M., et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153 (1998) 1425-1433
33. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., and Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (1995) 3964-3968
34. Ozdemir E., Kakehi Y., Okuno H., Habuchi T., Okada Y., and Yoshida O. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. J Urol 158 (1997) 206-211
35. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13 (2003) 49-58
36. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis 23 (2002) 381-387
37. de Oliveira L.R., Ribeiro-Silva A., and Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 36 (2007) 191-197
38. Gonzalez-Moles M.A., Galindo P., Gutierrez-Fernandez J., Sanchez-Fernandez E., Rodriguez-Archilla A., Ruiz-Avila I., et al. P53 protein expression in oral squamous cell carcinoma. survival analysis. Anticancer Res 21 (2001) 2889-2894
39. Ralhan R., Sandhya A., Meera M., Bohdan W., and Nootan S.K. Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer. Am J Pathol 157 (2000) 587-596
40. Liu C.J., Chang K.W., Chao S.Y., Kwan P.C., Chang S.M., Yen R.Y., et al. The molecular markers for prognostic evaluation of areca-associated buccal squamous cell carcinoma. J Oral Pathol Med 33 (2004) 327-334
41. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280 (2005) 26776-26787
42. Santarosa M., and Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 1654 (2004) 105-122
43. Kondo S., Barnett G.H., Hara H., Morimura T., and Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10 (1995) 2001-2006
44. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
45. Chene P. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res 2 (2004) 20-28